IL-35 Blocks Neutrophil Traps to Reduce Smoking-Related Asthma Inflammation
New research reveals how IL-35 therapy prevents neutrophil trap formation, offering hope for cigarette smoke-worsened asthma.
Summary
Researchers discovered that cigarette smoke worsens asthma by triggering neutrophil extracellular traps (NETs) that disrupt immune balance. The anti-inflammatory protein IL-35 blocks NET formation through a specific molecular pathway, reducing airway inflammation and restoring healthy immune responses. In mouse models, IL-35 treatment significantly improved lung function and reduced neutrophil-driven inflammation in smoking-related asthma. This finding could lead to new targeted therapies for the millions of people whose asthma is worsened by cigarette smoke exposure.
Detailed Summary
Cigarette smoke exposure dramatically worsens asthma outcomes, affecting millions worldwide and reducing the effectiveness of standard treatments. This comprehensive study reveals a previously unknown mechanism by which smoking triggers severe airway inflammation and identifies a potential therapeutic target.
Researchers used a mouse model combining house dust mite-induced asthma with cigarette smoke exposure to study the underlying mechanisms. They found that cigarette smoke dramatically increased neutrophil accumulation in the lungs and triggered the formation of neutrophil extracellular traps (NETs) - web-like structures that neutrophils release to fight infections but can cause harmful inflammation when overproduced.
The key discovery was that NETs act as a bridge between innate and adaptive immunity, enhancing dendritic cell antigen presentation and driving the differentiation of naive T cells toward inflammatory Th17 cells while suppressing protective regulatory T cells (Tregs). This creates a vicious cycle of inflammation that perpetuates asthma symptoms.
Treatment with IL-35, an anti-inflammatory protein, significantly improved outcomes by blocking NET formation through the gp130/STAT3/ferroptosis pathway. IL-35 therapy reduced neutrophil counts, restored the Th17/Treg balance, and improved lung function in the mouse model. Importantly, targeted degradation of NETs with DNase I was more effective than complete neutrophil depletion, suggesting that blocking NET formation rather than eliminating neutrophils entirely may be the optimal therapeutic approach.
These findings provide new insights into why cigarette smoke makes asthma so difficult to treat and suggest that IL-35-based therapies could offer hope for patients with smoking-related asthma exacerbations.
Key Findings
- Cigarette smoke exposure dramatically increased neutrophil counts and NET formation in asthma mouse models
- NETs enhanced dendritic cell antigen presentation and promoted inflammatory Th17 cell differentiation while suppressing protective Treg cells
- IL-35 treatment significantly reduced NET formation through the gp130/STAT3/ferroptosis signaling pathway
- Targeted NET degradation with DNase I was more effective than complete neutrophil depletion for reducing inflammation
- IL-35 therapy restored Th17/Treg immune balance and improved airway hyperresponsiveness in the mouse model
- RNA sequencing revealed significant upregulation of NET-associated genes in cigarette smoke-exposed asthma
- STAT3 phosphorylation promoted ferroptosis, which exacerbated NET release and subsequent immune dysfunction
Methodology
The study used female C57BL/6J mice (n=6 per group) in a house dust mite plus cigarette smoke exposure model over 5 weeks. Mice received intranasal HDM challenges three times weekly while being exposed to smoke from 10 cigarettes twice daily. Various interventions including IL-35, DNase I, and neutrophil depletion were tested. Statistical analysis used two-tailed t-tests and one-way ANOVA with Newman-Keuls post hoc testing.
Study Limitations
The study was conducted only in mouse models, and human clinical trials are needed to validate these findings. The research focused on acute exposure models and may not fully represent chronic smoking effects. The optimal dosing and delivery methods for IL-35 therapy in humans remain to be determined.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.